To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com or jmcguire@ohcmail.com
- CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- CONSOLIDATION/MAINTENANCE THERAPY FOLLOWING SECOND LINE THERAPY
- Study number:
- CLL 10 CC-5013-CLL-002 Celgene
- Protocol title:
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Fludarabine-Based Therapy
- Status:
- Open